PTPN1 and obesity disorder: PTP1B can serve to dephosphorylate and inactivate the IR and the leptin receptor–associated kinase JAK2; this is what laid the foundation for excitement about PTP1B as a therapeutic target for diabetes and obesity (71, 72).